Led by World-Renowned Scientists
Dr. Dustin Hines
Dustin is particularly interested in disorders of the nervous system that have metabolic and inflammatory components, ranging from depression and other psychiatric disorders to brain injury and neurodegeneration
Dr. Hines’ research ultimately is directed towards understanding how all of the signals and cells of the brain are orchestrated into the precise symphony that we call behavior.
A major objective of Dustin's research is the advancement of novel therapies for nervous system disorders. To pursue novel therapies, Dustin engages in both screening and testing of innovative compounds, but also mechanistic studies into the actions of currently available therapies to reverse engineer new targets.
CSO and Founder
Dr. Rochelle Hines
Rochelle is particularly interested in understanding neurotransmitter systems, receptor targets, and the ways that neurotransmitter systems interact with relevance for brain development, psychiatric disorders, and substance use disorders
The ultimate goal of Rochelle’s research is to improve our understanding of the formation and stabilization of specific synapse types during development, with an emphasis on inhibitory and neuromodulatory synapse types.
Rochelle Hines’ research is aimed at understanding neurodevelopmental processes under normal and pathological conditions, which include autism spectrum disorders, developmental epilepsies, and psychiatric disorders.
CEO and Founder
Paul is an experienced career entrepreneur and C-suite executive with vast capital market experience, as well as a licensed attorney.
Joe is an experienced entrepreneur, and an early stage advisor and investor. Joe is currently the
CEO of Rocketbook.
Aaron is an Instructor of Medicine at Harvard Medical School and the Sr. Director of Translational Research at Ovid Therapeutics.
Will is a partner at Mintz and has helped raise billions for his clients. Will also lectures at MIT’s Sloan School of Management.
Peter is a staunch global patent and brand protector for his corporate and university clients. Peter is a very strong chemist who is passionate about the science he protects.
Max is a Project Manager for Tessellate. Max’s background is in Corporate Strategy and Venture Capital.